Serum GP88 biomarker as a surrogate marker for disease progression in breast canc
血清 GP88 生物标志物作为乳腺癌疾病进展的替代标志物
基本信息
- 批准号:8058236
- 负责人:
- 金额:$ 11.33万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-09-27 至 2015-03-31
- 项目状态:已结题
- 来源:
- 关键词:AdjuvantAdjuvant ChemotherapyAdjuvant TherapyAdoptedAftercareAmerican College of Radiology Imaging NetworkArchivesBenignBiologicalBiological AssayBiological MarkersBiological MarkersBiopsyBreastCancer EtiologyCancer PatientCancer and Leukemia Group BCessation of lifeCharacteristicsClinicalClinical ResearchClinical TrialsClinical assessmentsDataDetectionDevelopmentDiagnosisDiagnosticDiagnostic radiologic examinationDiseaseDisease ProgressionDuctalEnrollmentEpitheliumEvaluationFaceFailureGrowth FactorHumanImageImage AnalysisImaging technologyIncidenceInvestigationLaboratoriesLesionLiquid substanceMagnetic Resonance ImagingMalignant NeoplasmsMalignant neoplasm of lungMammary Gland ParenchymaMeasurableMeasurementMeasuresMedicalMethodsMolecular AnalysisMonitorNeoadjuvant TherapyNo Evidence of DiseaseOperative Surgical ProceduresPC cell-derived growth factorPatientsPerformancePhasePlayPrimary NeoplasmProgressive DiseaseRadiationRecurrenceResearchResearch PersonnelRiskRoleSamplingSerumSmall Business Innovation Research GrantSpecialized Program of Research ExcellenceSpecimenStagingSurrogate MarkersTestingTherapeuticTimeTissuesToxic effectTreatment FailureTumor VolumeValidationWomanautocrinebasecancer recurrencecancer therapychemotherapycosthormone therapylymph nodesmalignant breast neoplasmmolecular markernoveloverexpressionresearch clinical testingresponsestandard of caresuccesstherapy outcometherapy resistanttooltreatment strategytumortumor progressiontumorigenesis
项目摘要
DESCRIPTION (provided by applicant): 40,000 women die annually in the US as a result of breast cancer (BC). Although BC can be controlled if detected early, a significant number is not detected until later and these patients are treated using therapies to control both primary tumor and micro-metastatic disease. Therapy response is monitored using imaging and clinical assessment. Failure to detect early progression is a missed opportunity to adopt suitable therapies at a time when their impact on the disease can be maximized. Identification and validation of surrogate markers for identification of disease progression would provide clinicians with timely information in the management of BC therapy. The purpose of this application is to investigate the performance characteristics of the novel 88kDa autocrine growth factor GP88 as a surrogate marker for disease progression in breast cancer patients. GP88 is a critical biological driver for proliferation, survival, and invasiveness and is over expressed in invasive ductal cancers while negative in benign lesions and normal breast tissue. Two tests were developed to measure GP88 expression in cancer specimens; an IHC test for tumor biopsies and an EIA to measure circulating GP88 in biological fluids that have been validated in clinical trials. Tissue GP88 expression was predictive marker of BC recurrence while serum GP88 was elevated in BC patients with progressive disease, but not in BC patients with no evidence of disease. The specific aims of this revised SBIR Phase I are to investigate GP88 as a surrogate marker for disease progression in BC patients enrolled in the I-SPY Trial. The I-SPY trial is a national study to identify biomarkers predictive of response to therapy throughout the treatment cycle for women with Stage 3 breast cancer in neoadjuvant setting. This trial enrolled 221 patients with tissue and serum samples collected at specific time points pre and post-treatment and subjects followed for three years post-therapy. 122 (55%) patients benefited from neo-adjuvant treatment, 40 (18%) patients received some benefit (tumors reduced by 10% - 40%) and 59 (27%) patients showed no benefit (disease progressed). Aims are: 1: Determine if serum/tissue GP88 levels are a surrogate marker to identify breast cancer patients not benefiting from on-going neo-adjuvant chemotherapy. We will determine if there is a correlation between GP88 level and decreased/increased tumor volume in chemo-naive patients undergoing neo-adjuvant chemotherapy. 2: Determine if serum GP88 can be used to identify breast cancer patients most likely to have recurrence following an initial benefit from neo-adjuvant therapy. We will determine if there is a quantifiable difference in the risk of recurrence between those patients with high and low serum or tissue GP88 levels, prior to commencing neo-adjuvant therapy. Upon completion of these specific aims, this investigation will evaluate GP88 as a surrogate to identify disease progression in patients undergoing chemotherapy and additionally if initial serum GP88 level prior to commencing therapy is correlated to risk of recurrence and will provide additional tools to clinicians to monitor therapy response and disease progression during and after treatment.
PUBLIC HEALTH RELEVANCE: (Lay) Breast cancer (BC) incidence in US women is second only to lung cancer and is one of the leading causes of cancer related death; 40,000 women die annually. Patients in whom BC is detected as having spread beyond the breast are treated with radiation, chemotherapy and/or hormonal therapy prior to potential surgery. During and post treatment, tumor response is monitored using x-ray and clinical evaluation, imprecise methods for detection of subtle changes in tumor size that may indicate treatment failure. Use of X-ray imaging is relatively infrequent, subjective and requires availability of prior studies. There are no easily available specific diagnostic markers, direct or surrogate, for monitoring disease activity in BC. We have identified GP88 as a biomarker that may be used as a surrogate for detection of tumor changes in BC patients undergoing therapy. Preliminary data in a small study demonstrated that GP88 can be identified in serum of BC patients and is elevated in patients with progressive disease but not in patients with "no evidence of disease" following therapy, thus indicating that it may be useful as a surrogate marker for assessing response to chemotherapy. This project will investigate the use of GP88 as a surrogate marker for detection of non-response to chemotherapy and will provide information that may enable clinicians to adopt 2nd or 3rd line therapies when they may be most effective and may save patients un-necessary toxicity and costs associated with ineffective 1st line therapy.
描述(由申请人提供):美国每年有40,000名妇女死于乳腺癌(BC)。虽然早期发现可以控制BC,但大量患者直到后来才被发现,这些患者使用治疗方法来控制原发肿瘤和微转移性疾病。使用影像学和临床评估来监测治疗反应。如果不能发现早期进展,就错过了在适当治疗对疾病影响可以最大化的时候采取适当治疗的机会。识别和验证替代标记物以识别疾病进展将为临床医生提供及时的BC治疗管理信息。本应用程序的目的是研究新型88kDa自分泌生长因子GP88作为乳腺癌患者疾病进展的替代标志物的性能特征。GP88是增殖、存活和侵袭性的关键生物学驱动因子,在浸润性导管癌中过表达,而在良性病变和正常乳腺组织中为阴性。开发了两种检测方法来测量GP88在癌症标本中的表达;一种用于肿瘤活检的免疫组化测试,以及一种用于测量生物体液中循环GP88的环评,这些都已在临床试验中得到验证。组织GP88的表达是BC复发的预测指标,而血清GP88在进展性BC患者中升高,但在无疾病证据的BC患者中没有升高。这项修订后的SBIR I期临床试验的具体目的是研究GP88作为I- spy试验中BC患者疾病进展的替代标志物。I-SPY试验是一项国家研究,旨在确定在新辅助治疗下3期乳腺癌妇女整个治疗周期中预测治疗反应的生物标志物。该试验招募了221名患者,在治疗前和治疗后的特定时间点收集组织和血清样本,并在治疗后随访三年。122例(55%)患者受益于新辅助治疗,40例(18%)患者获得一些益处(肿瘤缩小10% - 40%),59例(27%)患者没有获益(疾病进展)。目的是:1:确定血清/组织GP88水平是否可以作为鉴别乳腺癌患者是否受益于持续的新辅助化疗的替代标志物。我们将确定GP88水平与接受新辅助化疗的初次化疗患者肿瘤体积减小/增大之间是否存在相关性。2:确定血清GP88是否可用于鉴别最初接受新辅助治疗后最有可能复发的乳腺癌患者。在开始新辅助治疗之前,我们将确定血清或组织GP88水平高与低的患者在复发风险方面是否存在可量化的差异。在完成这些特定目标后,本研究将评估GP88作为替代物,以确定接受化疗的患者的疾病进展,以及开始治疗前的初始血清GP88水平是否与复发风险相关,并将为临床医生提供额外的工具,以监测治疗期间和治疗后的治疗反应和疾病进展。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ginette Serrero其他文献
Ginette Serrero的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ginette Serrero', 18)}}的其他基金
Pharmacology & human Phase 1 safety & dose escalation studies using anti-GP88 in aggressive breast cancer
药理
- 批准号:
10252075 - 财政年份:2018
- 资助金额:
$ 11.33万 - 项目类别:
Pharmacology & human Phase 1 safety & dose escalation studies using anti-GP88 in aggressive breast cancer
药理
- 批准号:
10245772 - 财政年份:2018
- 资助金额:
$ 11.33万 - 项目类别:
A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer
用于监测转移性乳腺癌的循环生物标志物
- 批准号:
9768982 - 财政年份:2017
- 资助金额:
$ 11.33万 - 项目类别:
A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer
用于监测转移性乳腺癌的循环生物标志物
- 批准号:
10477924 - 财政年份:2017
- 资助金额:
$ 11.33万 - 项目类别:
Granulin specific monoclonal antibodies to investigate their expression and role
颗粒蛋白特异性单克隆抗体研究其表达和作用
- 批准号:
8624365 - 财政年份:2013
- 资助金额:
$ 11.33万 - 项目类别:
Granulin specific monoclonal antibodies to investigate their expression and role
颗粒蛋白特异性单克隆抗体研究其表达和作用
- 批准号:
8729517 - 财政年份:2013
- 资助金额:
$ 11.33万 - 项目类别:
Targeted Therapy for Non Small Cell Lung Carcinoma: In vivo Feasibility Studies
非小细胞肺癌靶向治疗:体内可行性研究
- 批准号:
8312247 - 财政年份:2012
- 资助金额:
$ 11.33万 - 项目类别:
相似海外基金
3D Engineered Model of Microscopic Colorectal Cancer Liver Metastasis for Adjuvant Chemotherapy Screens
用于辅助化疗筛选的显微结直肠癌肝转移 3D 工程模型
- 批准号:
10556192 - 财政年份:2023
- 资助金额:
$ 11.33万 - 项目类别:
Developing Digital Pathology Biomarkers for Response to Neoadjuvant and Adjuvant Chemotherapy in Breast Cancer
开发数字病理学生物标志物以应对乳腺癌新辅助和辅助化疗
- 批准号:
10315227 - 财政年份:2021
- 资助金额:
$ 11.33万 - 项目类别:
Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colorectal Cancer: A Multicentre Phase II/III Randomised Controlled Trial (DYNAMIC-III)
循环肿瘤 DNA 分析为 III 期结直肠癌辅助化疗提供信息:多中心 II/III 期随机对照试验 (DYNAMIC-III)
- 批准号:
443988 - 财政年份:2021
- 资助金额:
$ 11.33万 - 项目类别:
Operating Grants
Establishment of new selection system for adjuvant chemotherapy of colorectal cancer
结直肠癌辅助化疗新选择体系的建立
- 批准号:
20K09011 - 财政年份:2020
- 资助金额:
$ 11.33万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improved survival by Helicobacter pylori-modulated immunity in gastric cancer patients with adjuvant chemotherapy
幽门螺杆菌调节免疫力可改善接受辅助化疗的胃癌患者的生存率
- 批准号:
19K09130 - 财政年份:2019
- 资助金额:
$ 11.33万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A new strategy of adjuvant chemotherapy for lung cancer based on the expression of anti-aging gene Klotho
基于抗衰老基因Klotho表达的肺癌辅助化疗新策略
- 批准号:
19K18225 - 财政年份:2019
- 资助金额:
$ 11.33万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Novel candidate factors predicting the effect of S-1 adjuvant chemotherapy of pancreatic cancer
预测胰腺癌S-1辅助化疗效果的新候选因素
- 批准号:
18K16337 - 财政年份:2018
- 资助金额:
$ 11.33万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Project 2-Metabolic Modulation of Myeloid-Derived Suppressor Cells to Increase Efficacy of Neo adjuvant Chemotherapy and Immunotherapy
项目2-骨髓源性抑制细胞的代谢调节以提高新辅助化疗和免疫疗法的疗效
- 批准号:
10005254 - 财政年份:2018
- 资助金额:
$ 11.33万 - 项目类别:
Radiogenomic tools for prediction of breast cancer neo-adjuvant chemotherapy response from pre-treatment MRI
通过治疗前 MRI 预测乳腺癌新辅助化疗反应的放射基因组学工具
- 批准号:
9763320 - 财政年份:2018
- 资助金额:
$ 11.33万 - 项目类别:
Analysis of the molecular mechanism for the prognostic biomarker of adjuvant chemotherapy
辅助化疗预后生物标志物的分子机制分析
- 批准号:
18K07341 - 财政年份:2018
- 资助金额:
$ 11.33万 - 项目类别:
Grant-in-Aid for Scientific Research (C)